|
SUNDAY,
SEPTEMBER 29, 2002 |
MONDAY,
SEPTEMBER 30, 2002 |
TUESDAY,
OCTOBER 1, 2002 |
WEDNESDAY,
OCTOBER 2, 2002 |
THURSDAY,
OCTOBER 3, 2002 |
| Orals |
Orals
|
Posters |
Orals
|
Posters |
Orals
|
Posters
|
Orals
|
Posters
|
| THURSDAY, OCTOBER 3, 2002 |
| 08:30 - 09:15 |
Hall A |
| PLENARY SESSION:
NOVEL PATHOGENETIC MECHANISMS IN AP1 |
Supported by unrestricted educational
grants from La Jolla Pharmaceuticals, USA and
Teva Pharmaceuticals, Israel |
Chairpersons:
|
To Be Advised
|
| 08:30 |
EFFECTS
OF aPL UPON THE MORPHOLOGY AND ANTICOAGULANT FUNCTION OF ANNEXIN-V
J.H. Rand, USA |
| 08:45 |
ROLE
OF THE MYD88 TRANSDUCTION SIGNALING PATHWAY INDUCED BY ANTI-BETA2
GLYCOPROTEIN I ANTIBODIES IN ENDOTHELIAL CELLS
E. Raschi, C. Testoni, D. Bosisio, M.O. Borghi, T. Koike,
A. Mantovani,
P.L. Meroni, Italy, Japan |
| 09:00 |
COMPLEMENT
ACTIVATION IS REQUIRED FOR
aPL-INDUCED THROMBOSIS
G. Girardi, J. Salmon, V.M. Holers, R.G. Espinola, X. Liu,
E.N. Harris,
S.S. Pierangeli, USA |
| |
| 09:15 - 10:00 |
Hall A |
| IVIG IN APS |
| Supported by an unrestricted
educational grant from ZLB, Switzerland |
Chairpersons:
|
I. Nur, Israel
H.J.A. Carp, Israel |
| 09:15 |
INTRAVENOUS
IMMUNOGLOBULIN IN PREGNANCY COMPLICATED BY APS
H.J.A. Carp, R.A. Asherson, Y. Shoenfeld, South Africa |
| 09:20 |
EFFICACY
AND SAFETY OF LONG-TERM IVIG TREATMENT IN PRIMARY APS
M. Galeazzi, R. Sgarlata, G. Morozzi, F. Bellisai,
G.D. Sebastiani,
G. Porciello, R. Marcolongo, Italy |
| 09:30 |
INTRAVENOUS
IMMUNOGLOBULIN THERAPY IN aPL-ASSOCIATED MISCARRIAGES
E.I. Konova, I.I. Ivanova, P.K. Petrova, H.D. Andreeva,
K.N. Popovski,
I.I. Popov, T.H. Lukanov, Bulgaria |
| 09:40 |
GAMMA-GLOBULIN
(IVIG) INHIBITS THE PRODUCTION OF MATRIX METALLOPROTEINASE-9
(MMP-9) IN MACROPHAGES
S. Shapiro, Y. Shoenfeld, B. Gilburd, E. Sobel, N.
Lahat, Israel |
| 09:50 |
DISCUSSION |
10:00 Coffee Break, Poster
Viewing and Exhibition Visit
|
| |
| 10:30 - 12:30 |
Hall A |
| THERAPIES
IN APS |
| Supported by an unrestricted
educational grant from AFR, Italy and La Jolla Pharmaceuticals,
USA |
Chairpersons:
|
T. Exner, Australia
To Be Advised |
| 10:30 |
DESIGN AND CLINICAL DEVELOPMENT OF A BETA-2
GPI B CELL TOLERAGEN FOR THE TREATMENT OF ANTIPHOSPHOLIPID
SYNDROME
M.D. Linnik, USA
|
| 10:50 |
APLASA
STUDY: PRIMARY THROMBOSIS PREVENTION IN ASYMPTOMATIC aPL
PATIENTS WITH LOW-DOSE ASPIRIN
D. Erkan, Y. Yazici, M.J. Harrison, M. Peterson,
L. Sammaritano,
M.D. Lockshin, USA
|
| 11:00 |
INHIBITION
OF RAS BY FARNESYLTHIOSALICYLATE SIGNIFICANLTLY REDUCES THE
LEVELS OF AUTOANTIBODIES IN TWO ANIMAL MODELS OF THE APS
A. Katzav, Y. Kloog, A.D. Korczyn, M. Blank, Y. Shoenfeld,
J. Chapman, Israel |
| 11:10 |
ANTIOXIDANT
TREATMENT DECREASES THE TITRE OF CIRCULATING ANTICARDIOLIPIN
ANTIBODIES
D. Ferro, G. Valesini, F. Conti, L. Iuliano, L. Loffredo,
F. Violi, Italy |
| 11:20 |
ENDOTHELIAL
MICROPARTICLES IN RECURRENT EARLY PREGNANCY LOSS
H.J.A. Carp, R. Dardik, O. Salomon, R. Eskaraev, A.
Inbal, Israel |
| 11:30 |
QUINACRINE
ADDED TO ONGOING THERAPEUTIC REGIMENS IS HIGHLY BENEFICIAL
IN ACTIVE SLE AND ATTENUATES aCL PRODUCTION
E. Toubi, A. Kessel, M. Rozenbaum, I. Rozner, D. Paran,
T. Golan, Israel |
| 11:40 |
ANTIPHOSPHOLIPID
ANTIBODIES IN PATIENTS WITH SLE / WITHOUT ANAMNESTIC THROMBOSES:
A POSSIBLE INDICATION FOR ASPIRIN
M. Taglietti, G. Balestrieri, M. Vianelli, C. Biasini
Rebaioli, I. Cavazzana,
M. Frassi, P. Airo', R. Gorla, F. Franceschini, R. Cattaneo,
A. Tincani, Italy
|
| 11:50 |
GESTATIONAL
AND NEONATAL OUTCOME IN PRIMARY APS
D. Faden, A. Lojacono, M. Motta, L. Decca, S. Zatti,
L. Barbetti, R. Gorla,
M. Taglietti, C. Biasini, G. Balestrieri, G. Chirico, A. Tincani,
Italy |
| 12:00 |
APS
IN PREGNANCY: A CONTROLLED TREATMENT TRIAL
R.G. Farquharson, S.M. Quenby, M. Greaves, UK |
| 12:10 |
GENERATION
OF ENDOTHELIAL PROCOAGULANT MICROPARTICLES :
A POTENTIAL PATHOGEN MECHANISM FOR THE THROMBOTIC COMPLICATIONS
OF APS
F. Dignat-George, V. Combes, L. Camoin-Jau, N. Bardin,
M. Sanmarco,
F. Sabatier, J.R. Harle, D. Arnoux, J. Sampol, France |
| 12:20 |
DISCUSSION |
12:30 Lunch Break, Poster Viewing
and Exhibition Visit
|
| |
| 14:00 - 16:00 |
Hall A |
| DIAGNOSTIC
KITS |
| Supported by an unrestricted
educational grant from Menarini/INOVA (Italy, USA) |
Chairpersons:
|
S. Pierangeli, USA
P. von Landenberg, Germany |
| 14:00 |
INTRODUCTORY COMMENTS: B2GPI AND ANTI-B2GPI
ANTIBODIES
P. De Groot, The Netherlands |
| 14:10 |
(aCL)
AND A-B2GPI ELISAS: THE STATE OF THE ART IN 2002
A. Tincani, M. Taglietti, M. Spunghi, M. Cinquini,
F. Allegri, G. Balestrieri,
G. Reber, T. Koike, K. Ichikawa, P. Meroni, M.C. Boffa, Italy,
Switzerland, Japan, France |
| 14:20 |
ASSAY
CONDITIONS FOR THE DETECTION OF IgG-ANTIPHOSPHATIDYLETHANOLAMINE
ANTIBODIES
M. Sanmarco, K. Mazodier, V. Roux, France |
| 14:30 |
THE
CORRELATION OF ANTIBODIES AGAINST B2GPI AND VARIOUS B2GPI
PEPTIDES WITH CLINICAL MANIFESTATIONS OF THE APS
I. Krause, Y. Shoenfeld, J. Sulkes, M. Blank, Israel |
| 14:40 |
APPLICATIONS
OF PHOSPHOLIPASES IN TESTING FOR LUPUS ANTICOAGULANTS AND
PHOSPHOLIPIDS
T. Exner, D. Ma, Australia |
| 14:50 |
THE
ORIENTATION OF B2GPI ON THE PLATE IS IMPORTANT FOR THE BINDING
OF A-B2GPI AUTOANTIBODIES BY ELISA
G.M. Iverson, E. Matsuura, E.J. Victoria, K.A. Cockerill,
M.D. Linnik, USA, Japan |
| 15:00 |
ANTI-PHOSPHOLIPID
ANTIBODIES AND MONOCLONAL A-B2GPI INHIBIT aPC ANTICOAGULANT
ACTIVITY ON OXIDIZED PHOSPHOLIPID
O. Safa, K. Hensley, C.T. Esmon, N.L. Esmon, USA |
| 15:10 |
PROTEIN
C GLOBAL ASSAY IN THE EVALUATION OF WOMEN WITH IDIOPATHIC
PREGNANCY LOSS
G. Sarig, N. Lanir, R. Hoffman, B. Brenner, Israel |
| 15:20 |
USE
OF PLASMA SPIKED WITH MONOCLONAL ANTIBODIES AS A REFERENCE
MATERIAL FOR LUPUS ANTICOAGULANT SCREENING; EXPERIENCE WITH
THE UK NEQAS (BLOOD COAGULATION) PROFICIENCY TESTING SCHEME
I. Jennings, S. Kitchen, T.A.L. Woods, J. Arnout, F.E.
Preston, UK, Belgium |
| 15:30 |
DETERMINATION
AND SIGNIFICANCE OF AUTOANTIBODIES TO OXLIG-1/B2GPI COMPLEX
IN PATIENTS WITH APS
D. Lopez, I. Garcia-Valladares, K. Dier, C. Fink, K. Kobayashi,
E. Matsuura, L. Lopez, USA, Japan |
| 15:40 |
A
SIMPLE SEMI-QUANTITATIVE METHOD FOR LUPUS ANTICOAGULANT ACTIVITY
USING PHOSPHATIDYLSERINE DEPENDENT MONOCLONAL ANTIPROTHROMBIN
ANTIBODY
T. Atsumi, M. Ieko, K. Ichikawa, T. Horita, S. Jodo,
Y. Amasaki,
T. Koike, Japan |
| 15:50 |
HETEROGENEITY
OF ANTI-PROTHROMBIN ANTIBODIES, DETECTED BY DIFERENT ELISAs
S. Cucnik, T. Kveder, B. Bozic, Slovenia |
16:00 Coffee Break, Poster
Viewing and Exhibition Visit
|
| |
| 16:30 - 18:00 |
Hall A |
| APOPTOSIS,
ANTIBODIES AND APS |
| Supported by an unrestricted
educational grant from Pharmacia Diagnostics, Germany |
Chairpersons:
|
A.E. Gharavi, USA
M. Blank, Israel |
| 16:30 |
PROTHROMBIN-DEPENDENT
LUPUS ANTICOAGULANT ANTIBODIES BIND TO APOPTOTIC CELLS
J. Rauch, P. D'Agnillo, R. Subang, J.S. Levine, Canada,
USA |
| 16:45 |
PHOSPHATIDYLSERINE
EXTERNALIZATION DURING DIFFERENTIATION AND APOPTOSIS ARE INDEPENDENT
PROCESSES IN TROPHOBLAST
N.S. Rote, B. Xu, L. Lin, V. Shivaswamy, M.N. Kent,
USA |
| 17:00 |
ANTIPHOSPHOLIPID
ANTIBODIES AND RECURRENT FIRST TRIMESTER MISCARRIAGE: ARE
aPL CAUSITIVE? IS TREATMENT EFFICACIOUS?
H.J.A. Carp, Y. Shoenfeld, Israel |
| 17:10 |
OXIDIZED
LDL AS A RISK FACTOR OF THROMBOSIS IN APS
E. Matsuura, Japan |
| 17:20 |
ANTI-PIG
B2GPI ANTIBODIES IN APS SERA
A. Gries, Austria |
| 17:30 |
INCREASED
LEVELS OF ANTIPHOSPHOLIPID ANTIBODIES ARE ASSOCIATED WITH
INCREASED LYMPHOCYTE APOPTOSIS IN LUPUS PATIENTS PRESENTING
WITH DIFFUSE NEUROPSYCHIATRIC DISEASE
L.M. Silva, W. Sarti, A.B. Garcia, E.A. Donadi, Brazil |
| 17:40 |
ANTI-PAF
ANTIBODIES AND OTHER NON-TRADITIONAL AND TRADITIONAL RISK
FACTORS IN BORDERLINE HYPERTENSION
J. Frostegard, G-Z. Fei, R. Wu, G. Pockley, C. Lemne,
U. De Faire, Sweden, UK |
17:50
|
EVALUATION
OF A RENEWED CARDIOLIPIN ABS
ASSAY - REQUIREMENTS OF GMP CONFIRM PRODUCTION
W. Papisch, T. Frey, B. Berg, Germany |
SUNDAY,
SEPTEMBER 29, 2002 |
MONDAY,
SEPTEMBER 30, 2002 |
TUESDAY,
OCTOBER 1, 2002 |
WEDNESDAY,
OCTOBER 2, 2002 |
THURSDAY,
OCTOBER 3, 2002 |
| Orals |
Orals
|
Posters |
Orals
|
Posters |
Orals
|
Posters
|
Orals
|
Posters
|
|
|
